Kazia Therapeutics (ASX:KZA) to present paxalisib’s positive Phase II glioblastoma data at SNO

  • November 18, 2020 03:15 PM AEDT
  • Hina Chowdhary
    Director, Equities Research Hina Chowdhary
    1706 Posts

    Hina Chowdhary is the Director, Equity Research at Kalkine and has an extensive experience of about 15 years in the area of Research, which includes 5+ years in Equities Research particularly.She has earned a Master of Science degree from the renowne...

Kazia Therapeutics (ASX:KZA) to present paxalisib’s positive Phase II glioblastoma data at SNO


  • Kazia Therapeutics has announced that it will present the summary of paxalisib’s new Phase II study data at the SNO Annual Meeting to be held during 19-21 November.
  • The new interim data of paxalisib in glioblastoma is consistent with the previous results validating the favourable efficacy and safety profile of the molecule.
  • The Company anticipates the Phase II study completion in the first half of CY21.
Gold MTF non-AMP

ASX-listed oncology-focused biotechnology company Kazia Therapeutics Limited (ASX:KZA, NASDAQ:KZIA) witnessed its share price surge on the ASX following the announcement that it would present a summary of new paxalisib data at the SNO Annual Meeting.

The shares of KZA were trading at A$1.575 (at AEDT 3:09 PM), rising sharply by 32.352%. The Company’s market capitalisation stands at A$150.13 million.

Let us discuss in detail what Kazia Therapeutics announced recently-

About Kazia Therapeutics Limited

Sydney-headquartered biotechnology player Kazia Therapeutics Limited is engaged in developing therapies across several oncology indications. The Company’s drug pipeline includes two clinical-stage drug development candidates- paxalisib and cantrixil.

Summary of new paxalisib Phase IIa data presented at SNO

On 18 November 2020, Kazia Therapeutics Limited announced that the Company would present a summary of new paxalisib data at the Society for Neuro-Oncology (SNO) Annual Meeting, to be held from 19-21 November 2020 (virtually).

KZA stated that the new interim data of paxalisib in Phase II clinical trial in glioblastoma is highly consistent with the prior data.

The interim results of the study demonstrate a median progression-free survival of 8.4 months versus 5.3 months for the existing standard of care, temozolomide. The median overall survival of 17.5 months was reported versus 12.7 months for temozolomide.

Moreover, the Company anticipates that the trial will be complete in the first half of the calendar year 2021. However,  KZA believes that the results, so far, have already given useful information to support the development of paxalisib.

Kazia CEO Dr James Garner commented-

Mr Garner also added that Kazia Therapeutics has moved into the operational phase of the GBM AGILE pivotal study. He said that the study would be the primary focus of the Company’s work in glioblastoma.

Paxalisib Phase IIa Study in Brief

The current Phase IIa study (NCT03522298) aims to investigate the safety, tolerability, along with the clinical activity of paxalisib in patients having newly-diagnosed GBM and unmethylated MGMT promotor status, after the surgical resection and chemoradiotherapy.

Next Steps: Final data anticipated in the first half of 2021

  • The Phase II study of paxalisib is ongoing, with the final results anticipated in H1 CY21.
  • The Company stated that the paxalisib arm of the GBM AGILE study has stepped into an operational phase, and the first patient is expected in the first quarter CY21.
  • The St Jude study in DIPG continues, with final results likely in H1 CY21.



The website https://kalkinemedia.com/au is a service of Kalkine Media Pty. Ltd. (Kalkine Media) A.C.N. 629 651 672. The principal purpose of the content on this website is to provide factual information only and does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stock of the company (or companies) or engage in any investment activity under discussion. We are neither licensed nor qualified to provide investment advice through this platform. In providing you with the content on this website, we have not considered your objectives, financial situation or needs. You should make your own enquiries and obtain your own independent advice prior to making any financial decisions.
Some of the images that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed on this website unless stated otherwise. The images that may be used on this website are taken from various sources on the web and are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it below the image. The information provided on the website is in good faith, however Kalkine Media does not make any representation or warranty regarding the content, accuracy, or use of the content on the website.


We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK